In patients on clopidogrel after DES, the concomitant administration of CCB was associated with reduced platelet inhibition and increased post discharge adverse events. However, CCB were not associated with adverse clinical events by multivariable analysis, suggesting confounding by comorbidities and presenting characteristics. Thus, CCB may be used as indicated in patients on clopidogrel after DES.
Background: In prior studies non-smokers have been reported to have reduced clinical benefit of clopidogrel treatment as compared to smokers. This new "smoker's paradox" has been explained by the increase in the production of clopidogrel's active metabolite in smokers. We examined this relationship in the large scale Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Methods: Patients had P2Y12 platelet reactivity testing using the VerifyNow pointof-care assay after successful, non-complicated PCI with DES implantation. All patients were treated with aspirin and clopidogrel, and were followed for 1 year. Current smoking status was defined as active smoking within 1 month prior to enrollment. Results: Of the 8,583 patients enrolled, 1,939 (22.6%) pts were current smokers and 6,644 (77.4%) were not. Major baseline characteristics, P2Y12 results and 1-year events are summarized in the Table. By multivariable analysis, current smoking status was inversely associated with platelet reactivity (p¼0.0002). In propensity-stratified proportional hazards regression models, current smoking was independently associated with 1-year all-cause mortality (HR Conclusions: Current smokers treated with clopidogrel after non-complicated PCI have greater levels of platelet inhibition compared with non-smokers. However, after adjustment for differences in baseline characteristics, smoking status was independently associated with mortality at 1 year. This analysis does not support the existence of clopidogrel-related "smoker's paradox". 
